Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2025)

Ultragenyx Pharmaceutical has reported EBT Margin over the past 10 years, most recently at 61.6% for Q4 2025.

  • Quarterly EBT Margin rose 1907.0% to 61.6% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 84.84% through Dec 2025, up 1641.0% year-over-year, with the annual reading at 84.84% for FY2025, 1641.0% up from the prior year.
  • EBT Margin was 61.6% for Q4 2025 at Ultragenyx Pharmaceutical, up from 112.26% in the prior quarter.
  • Over five years, EBT Margin peaked at 399.18% in Q4 2021 and troughed at 263.3% in Q3 2022.
  • The 5-year median for EBT Margin is 124.42% (2025), against an average of 80.46%.
  • Year-over-year, EBT Margin plummeted -54750bps in 2022 and then skyrocketed 52708bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 399.18% in 2021, then crashed by -137bps to 148.32% in 2022, then soared by 355bps to 378.76% in 2023, then tumbled by -121bps to 80.67% in 2024, then increased by 24bps to 61.6% in 2025.
  • Per Business Quant, the three most recent readings for RARE's EBT Margin are 61.6% (Q4 2025), 112.26% (Q3 2025), and 68.47% (Q2 2025).